Free Trial
NASDAQ:LENZ

LENZ Therapeutics (LENZ) Stock Price, News & Analysis

LENZ Therapeutics logo
$35.50 +1.18 (+3.44%)
(As of 11/22/2024 ET)

About LENZ Therapeutics Stock (NASDAQ:LENZ)

Key Stats

Today's Range
$33.85
$36.09
50-Day Range
$20.91
$37.25
52-Week Range
$14.42
$38.93
Volume
88,014 shs
Average Volume
160,089 shs
Market Capitalization
$976.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.40
Consensus Rating
Buy

Company Overview

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

LENZ Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
12th Percentile Overall Score

LENZ MarketRank™: 

LENZ Therapeutics scored higher than 12% of companies evaluated by MarketBeat, and ranked 902nd out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    LENZ Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    LENZ Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about LENZ Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for LENZ Therapeutics are expected to decrease in the coming year, from ($2.09) to ($2.54) per share.

  • Price to Book Value per Share Ratio

    LENZ Therapeutics has a P/B Ratio of 4.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about LENZ Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    9.22% of the float of LENZ Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LENZ Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in LENZ Therapeutics has recently increased by 2.99%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    LENZ Therapeutics does not currently pay a dividend.

  • Dividend Growth

    LENZ Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.22% of the float of LENZ Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LENZ Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in LENZ Therapeutics has recently increased by 2.99%, indicating that investor sentiment is decreasing.
  • News Sentiment

    LENZ Therapeutics has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for LENZ Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    2 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    38.40% of the stock of LENZ Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about LENZ Therapeutics' insider trading history.
Receive LENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LENZ Stock News Headlines

HC Wainwright Expects Higher Earnings for LENZ Therapeutics
This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
See More Headlines

LENZ Stock Analysis - Frequently Asked Questions

LENZ Therapeutics' stock was trading at $16.20 at the start of the year. Since then, LENZ stock has increased by 119.1% and is now trading at $35.50.
View the best growth stocks for 2024 here
.

LENZ Therapeutics, Inc. (NASDAQ:LENZ) issued its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.09.

Top institutional shareholders of LENZ Therapeutics include Geode Capital Management LLC (1.23%), State Street Corp (1.05%), Parkman Healthcare Partners LLC (0.51%) and Charles Schwab Investment Management Inc. (0.45%). Insiders that own company stock include Ra Capital Management, LP and James W Mccollum.
View institutional ownership trends
.

Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that LENZ Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
11/06/2024
Today
11/23/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/05/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:LENZ
Previous Symbol
NASDAQ:LENZ
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.40
High Stock Price Target
$38.00
Low Stock Price Target
$32.00
Potential Upside/Downside
-0.3%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Net Income
$-124,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.83 per share

Miscellaneous

Free Float
16,941,000
Market Cap
$976.25 million
Optionable
N/A
Beta
0.36
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:LENZ) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners